Stroke RSS Page 18

Filtered By:
Condition: Heart Failure
Cancer: Cancer
Education: Study

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 449 results found since Jan 2013.

Cardiovascular outcomes and rates of fractures and falls among patients with brand-name versus generic L-thyroxine use
ConclusionsWe found no significant differences in cardiovascular outcomes and rates of falls and fractures for patients who filled brand versus generic L-thyroxine.
Source: Endocrine - June 5, 2021 Category: Endocrinology Source Type: research

Associations Between Sleep Quality and Health Span: A Prospective Cohort Study Based on 328,850 UK Biobank Participants
ConclusionHealthy sleep quality was associated with a reduced risk of premature end of health span, suggesting healthy sleep behavior may extend health span. However, further studies are suggested for confirmation of causality and potential mechanism.
Source: Frontiers in Genetics - June 15, 2021 Category: Genetics & Stem Cells Source Type: research

Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: a French population-based study on prostate cancer patients
CONCLUSION: Our study provides knowledge on abiraterone and enzalutamide real-life safety profiles, especially for events leading to hospitalisation. Despite several limitations, including the lack of clinical data, the safety signal for AKI under abiraterone is in line with results of an analysis of the French pharmacovigilance database, which requires further specific investigations. Enlightening the clinicians' therapeutic choices for patients treated for prostate cancer, our study should lead to clinicians to be cautious in the use of abiraterone.PMID:34224605 | DOI:10.1111/bcp.14972
Source: Clinical Prostate Cancer - July 5, 2021 Category: Cancer & Oncology Authors: Lucie-Marie Scailteux Fabien Despas Fr édéric Balusson Boris Campillo-Gimenez Romain Mathieu S ébastien Vincendeau Andr é Happe Emmanuel Nowak Sandrine Kerbrat Emmanuel Oger Source Type: research

Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study
CONCLUSION: Our results indicate an increased risk for ischemic heart disease and arrhythmia in patients treated for more than four years with AIs. This should be considered in the risk-benefit assessment concerning endocrine therapy.PMID:34265496 | DOI:10.1016/j.breast.2021.07.004
Source: Breast - July 15, 2021 Category: Cancer & Oncology Authors: Maria Sund Miguel Garcia-Argibay Hans Garmo Johan Ahlgren Anna-Karin Wennstig Irma Fredriksson Henrik Lindman Antonis Valachis Source Type: research

Summary: International Kidney Cancer Symposium
Conclusions: Ideal ischemia time is 20-25 minutes or less improves short and long term renal function. >25 minutes carried 5 year risk of new onset stage 4 CKD No differences on GFR for cold vs. warm ischemia times Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR. No ischemia preserves renal function better than warm. Longer cold ischemia times were equivalent to shorter warm ischemia times. Quality and quantity of the remaining kidney is associated with ultimate renal function. Robotics in RCC Surgery Gennady Bratslavsky, MD The opening question ...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Newly Developed Highly Bioavailable Curcumin Formulation, curcuRouge < sup > TM < /sup > , Reduces Neutrophil/Lymphocyte Ratio in the Elderly: A Double-Blind, Placebo-Controlled Clinical Trial
J Nutr Sci Vitaminol (Tokyo). 2021;67(4):249-252. doi: 10.3177/jnsv.67.249.ABSTRACTElevated neutrophil/lymphocyte ratio (NLR) has been reported as a sensitive marker for predicting poor prognosis in chronic inflammation-based diseases such as stroke, heart failure, cancers, and diabetes, as well as acute inflammatory diseases such as bacterial and viral infections, including COVID-19. NLR is also known to increase with age and is considered to be an aging marker. We conducted a double-blind, placebo-controlled trial in elderly volunteers to examine the effect of a newly developed, highly bioavailable curcumin formulation (...
Source: Journal of Nutritional Science and Vitaminology - September 2, 2021 Category: Nutrition Authors: Atsuhiro Kishimoto Atsushi Imaizumi Hiromichi Wada Hajime Yamakage Noriko Satoh-Asahara Tadashi Hashimoto Koji Hasegawa Source Type: research

Association Between a Body Shape Index and Subclinical Carotid Atherosclerosis in Population Free of Cardiovascular and Cerebrovascular Diseases
CONCLUSIONS: ABSI, as a novel anthropometric indicator compared with traditional indices, was found to have a closer relationship with subclinical carotid atherosclerosis, even in populations free of hypertension, diabetes, and hyperlipidemia.PMID:34483222 | DOI:10.5551/jat.62988
Source: Journal of Atherosclerosis and Thrombosis - September 6, 2021 Category: Cardiology Authors: Xiaotian Ma Lihong Chen Wenchao Hu Lanjie He Source Type: research

ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also suppor...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20